{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial Comparing Incidence of Catheter-Related Bloodstream Infections in Central Venous Access Devices"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation methods varied, with some studies using appropriate randomisation and allocation concealment."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Paired meta-analyses showed a lower incidence of CRBSIs in the peripherally inserted central catheter (PICC) group compared to the central venous catheter (CVC) group and the totally implantable venous access port (TIVAP) group."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the incidence of catheter-related bloodstream infections (CRBSIs) among different central venous access devices (CVADs)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of CRBSIs, measured over the study duration."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation methods varied, with some studies using appropriate randomisation and allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not feasible due to the nature of the intervention."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Five RCTs were included, with a total of 962 participants."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Paired meta-analyses showed a lower incidence of CRBSIs in the peripherally inserted central catheter (PICC) group compared to the central venous catheter (CVC) group (RR = 0.23, 95% CI 0.13\u20130.43, p < 0.00001) and the totally implantable venous access port (TIVAP) group (RR = 0.45, 95% CI 0.23\u20130.87, p = 0.02)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}